Pharma firms seek to list R&D arms, but funding risks remain
Drug expert expresses doubts over ability of Indian markets to fund and understand business models
Reply to comment
I have 2 questions:
1. How is the de-merger tide going to impact the Indian-Western pharma alliances?
2. Does Indian stock exchange reward short term cash flow growth rather than future benefits?
Gaurav